In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 22013-33-8, name is 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine, introducing its new discovery. Application In Synthesis of 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine
Mesolimbic selective antipsychotic arylcarbamates
4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine has been linked to various arylcarbamates to obtain compounds having affinity for dopamine-D1 and -D2, serotonin 5HT(2A) and alpha1-adrenoceptors. When linkers with restricted flexibility are used, the biological activity is reduced indicating that a bended conformation is needed in this series of bioactive molecules. Compounds with a relatively low D2/5HT(2A) affinity ratio in receptor binding experiments and high affinity for the alpha1-adrenoceptors exhibit a pharmacological profile which suggests a preferential effect on the mesocorticolimbic dopaminergic system and an ‘atypical’ antipsychotic activity.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 22013-33-8, and how the biochemistry of the body works.Application In Synthesis of 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine
Reference£º
Benzodioxan,
1,4-Benzodioxane | C8H8O2 – PubChem